| | | | Sincerely, | |
| | | |
|
|
| | | |
James C. Foster
Chairman, President and Chief Executive Officer |
|
| | | | By Order of the Board of Directors | |
| | | |
|
|
| | | |
Matthew L. Daniel
Corporate Secretary |
|
|
Time and Date:
|
| | 8:00 a.m. on Tuesday, May 9, 2023 | |
|
Place:
|
| | Cooley LLP, 500 Boylston Street, Boston, MA 02116 | |
|
Record Date:
|
| | March 16, 2023 | |
| |
Proposal
|
| |
Board Vote Recommendation
|
| |
| | Management Proposals | | | | | |
| | Election of Directors | | |
FOR each director nominee
|
| |
| | Advisory Vote to Approve Executive Officer Compensation | | |
FOR
|
| |
| | Advisory Vote on Frequency of Future Votes on Executive Compensation | | |
ANNUAL
|
| |
| | Ratification of Independent Registered Public Accounting Firm | | |
FOR
|
| |
| | Shareholder Proposal | | | | | |
| | Shareholder Proposal described in this Proxy Statement | | |
AGAINST
|
| |
| | | | | | | | | |
Director
Since |
| | | | | | | | | | |
Current Committee Memberships
|
| | ||||||||||||||||||||
| |
Name
|
| | |
Age
|
| | |
Occupation
|
| | |
Independent
|
| | |
AC
|
| | |
CC
|
| | |
CGNC
|
| | |
SPCAC
|
| | |
STC
|
| | |
FC
|
| | ||||
| |
James C. Foster
|
| | |
72
|
| | |
1989
|
| | |
Chair, President and CEO of Charles River Laboratories International, Inc.
|
| | | | | | | | | | | | | | | | | | |
|
| | | | | | | | | |
| |
Nancy C. Andrews
|
| | |
64
|
| | |
2020
|
| | |
Executive Vice President and Chief Scientific Officer at Boston Children’s Hospital. Former Professor of Pharmacology & Cancer Biology, Duke University School of Medicine. Former Dean of Duke University School of Medicine and Vice Chancellor of Academic Affairs of Duke University.
|
| | |
|
| | | | | | | | | | |
|
| | | | | | |
|
| | | | | |
| |
Robert Bertolini
|
| | |
61
|
| | |
2011
|
| | |
Former President and CFO of Bausch and Lomb Incorporated and former Executive Vice President and Chief Financial Officer of Schering-Plough Corp.
|
| | |
|
| | |
|
| | | | | | | | | | |
|
| | | | | | | | | |
| |
Deborah T. Kochevar
|
| | |
66
|
| | |
2008
|
| | |
Senior Fellow, The Fletcher School of Law and Diplomacy, Tufts University. Dean Emerita of Cummings School of Veterinary Medicine, Tufts University. Former Provost and Senior Vice President ad interim, Tufts University.
|
| | |
|
| | | | | | | | | | |
|
| | | | | | |
|
| | | | | |
| |
George Llado, Sr.
|
| | |
57
|
| | |
2020
|
| | |
Former Senior Vice President and Chief Information Officer of Alexion Pharmaceuticals, Inc.
|
| | |
|
| | | | | | |
|
| | |
|
| | | | | | |
|
| | | | | |
| |
Martin W. Mackay
|
| | |
67
|
| | |
2017
|
| | |
Co-Founder and CEO of Rallybio Corporation. Former Chief of R&D, AstraZeneca and Former Chief of R&D, Alexion Pharmaceuticals, Inc.
|
| | | | | | | | | | | | | | | | | | | | | | |
|
| | |
|
| |
| |
George E. Massaro
|
| | |
75
|
| | |
2003
|
| | |
Former Vice Chair, Huron Consulting Group, Inc.
|
| | |
|
| | |
|
| | |
|
| | | | | | | | | | | | | | | | | |
| |
C. Richard Reese
|
| | |
77
|
| | |
2007
|
| | |
Former CEO and Chair of Iron Mountain Incorporated
|
| | |
|
| | | | | | |
|
| | | | | | |
|
| | | | | | | | | |
| |
Craig B. Thompson
|
| | |
70
|
| | |
2022
|
| | |
President Emeritus, Memorial Sloan Kettering Cancer Center. Member of the Sloan Kettering Institute and the Department of Medicine, Memorial Sloan Kettering Cancer Center.
|
| | |
|
| | | | | | | | | | | | | | |
|
| | |
|
| | | | | |
| |
Richard F. Wallman
|
| | |
71
|
| | |
2011
|
| | |
Former Senior Vice President and CFO, Honeywell International, Inc.
|
| | |
|
| | | | | | |
|
| | | | | | |
|
| | | | | | |
|
| |
| |
Virginia M. Wilson
|
| | |
68
|
| | |
2019
|
| | |
Retired Senior Executive Vice President and Chief Financial Officer, TIAA
|
| | |
|
| | |
|
| | | | | | |
|
| | | | | | | | | | | | | |
| | What We Do | | | |||
| |
✓
Align our executive pay with performance, with a substantial proportion of executive compensation tied to “at risk” elements
|
| |
✓
Include a “clawback” provision in our Corporate Governance Guidelines that applies to our cash and equity incentive awards
|
| |
| |
✓
Set challenging performance objectives
|
| |
✓
Prohibit hedging and pledging of company shares
|
| |
| |
✓
Appropriately balance short- and long-term incentives
|
| |
✓
Retain an independent compensation consultant to advise the Compensation Committee
|
| |
| |
✓
Align executive compensation with shareholder returns through performance-based equity incentive awards
|
| |
✓
Include caps on individual payouts in short- and long-term incentive plans
|
| |
| |
✓
Use appropriate peer groups methodology and revenue regression when evaluating the competitiveness of compensation
|
| |
✓
Hold an annual “say-on-pay” advisory vote
|
| |
| |
✓
Maintain meaningful equity ownership guidelines
|
| |
✓
Maintain a Compensation Committee composed entirely of independent directors
|
| |
| |
✓
Engage in substantial outreach efforts with our major shareholders to gather feedback, including with respect to executive compensation
|
| |
✓
Conduct an annual risk assessment of our pay practices
|
| |
| | What We Don’t Do | | | |||
| |
✘
No contracts with multi-year guaranteed salary increases or non-performance bonus arrangements
|
| |
✘
No excessive perquisites
|
| |
| |
✘
No “single trigger” equity vesting provisions in our current equity award plans
|
| |
✘
No change-in-control tax gross-ups
|
| |
| |
✓
Majority voting standard
|
| |
✓
Expectation of director attendance at 75%+ meetings
|
| |
| |
✓
Mandatory director retirement age
|
| |
✓
Proxy access by-law
|
| |
| |
✓
Annual director and committee assessments
|
| |
✓
Commitment to ESG principles
|
| |
| |
✓
Lead Independent Director
|
| |
✓
Code of Business Conduct and Ethics
|
| |
| |
✓
Independent Board Committee chairs
|
| |
✓
Information security risk oversight by Audit Committee
|
| |
| |
✓
Stock ownership requirements
|
| |
✓
Corporate strategy and risk oversight by Board
|
| |
| |
✓
Political Contribution Policy
|
| | | | |
| | |
2022
|
| |
2021
|
| ||||||
Audit fees
|
| | | $ | 6,151,413 | | | | | $ | 6,479,044 | | |
Audit related fees
|
| | | | 2,959,018 | | | | | | 3,258,316 | | |
Tax fees
|
| | | | 980,353 | | | | | | 1,013,393 | | |
All other fees
|
| | | | 646,394 | | | | | | 1,646,751 | | |
Total
|
| | | $ | 10,737,178 | | | | | $ | 12,397,504 | | |
|
Name and Age as of the 2023
Annual Meeting |
| | | | |
Position, Principal Occupation, Business Experience and Directorships
|
|
|
James C. Foster (he/him/his)
|
| |
72
|
| |
Mr. Foster joined us in 1976 as General Counsel and over his tenure has held various staff and managerial positions. Mr. Foster was named President in 1991, Chief Executive Officer in 1992, and Chair in 2000. Mr. Foster has been a director since 1989.
Mr. Foster was selected to serve as a director on our Board due to his role as our Chief Executive Officer, his depth of knowledge of us and our operations, his acute business judgment, extensive familiarity with the businesses in which we compete, and his lengthy experience with us.
|
|
|
Name and Age as of the 2023
Annual Meeting |
| | | | |
Position, Principal Occupation, Business Experience and Directorships
|
|
|
Nancy C. Andrews, M.D., Ph.D (she/her/hers)
|
| |
64
|
| |
Executive Vice President and Chief Scientific Officer at Boston Children’s Hospital since December 2021. Served as Professor of Pediatrics and Professor of Pharmacology & Cancer Biology at Duke University from 2007 to December 2021 (and the Nanaline H. Duke endowed chair from 2013 to 2020). From 2007 to 2017, Dr. Andrews served as Dean of the Duke University School of Medicine and Vice Chancellor for Academic Affairs at Duke University. From 2003 to 2007, she served as dean for Basic Sciences and Graduate Studies and Professor of Pediatrics at Harvard University Medical School. From 1999 to 2003, she served as director of the Harvard-Massachusetts Institute of Technology M.D./Ph.D. Program, and the principal investigator of its MSTP grant. From 1993 to 2006, she was a biomedical research investigator of the Howard Hughes Medical Institute. Dr. Andrews served on the Executive Committee of the MIT Corporation, and is currently Chair of the Board of Directors of the American Academy of Arts and Sciences, and a member of the Scientific Advisory Board of Dyne Therapeutics. She is an elected member of both the National Academy of Medicine and the National Academy of Sciences and currently serves on the Council of the National Academy of Sciences. She is a former Chair of the Board of Directors of the Burroughs Wellcome Fund and a former member of the Scientific Management Review Board at the National Institutes of Health. Dr. Andrews also serves on the boards of directors of Novartis International AG and Maze Therapeutics. Dr. Andrews has been a director since February 2020.
Dr. Andrews was selected for the Board in recognition of her distinct perspective as an accomplished physician, scientific researcher, professor, and senior administrator at leading academic institutions and hospitals. She brings to the Board extensive scientific leadership and expertise in oncology, genetics, and pediatric research. Dr. Andrews’ training and experience are particularly suited to understanding and providing insights into the research and development process, which further enhances our position as the partner of choice for our clients’ early-stage drug development programs.
|
|
|
Name and Age as of the 2023
Annual Meeting |
| | | | |
Position, Principal Occupation, Business Experience and Directorships
|
|
|
Robert Bertolini (he/him/his)
|
| |
61
|
| |
President and Chief Financial Officer of Bausch & Lomb Incorporated from February 2013 to August 2013 (until its acquisition by Valeant Pharmaceuticals International, Inc. (n/k/a Bausch Health Companies Inc.)). Mr. Bertolini served as Executive Vice President and Chief Financial Officer at Schering-Plough Corp. from November 2003 until November 2009 (until its merger with Merck & Co) with responsibility for tax, accounting, and financial asset management. Prior to joining Schering-Plough, Mr. Bertolini spent 20 years at PricewaterhouseCoopers LLP, ultimately leading its global pharmaceutical industry practice. Mr. Bertolini served as a director of Bristol-Meyers Squibb Company from 2017 to May 2021, of Actelion from 2011 to 2017, and of Indorsia, Ltd., a Swiss public company, from 2017 until May 2020. Mr. Bertolini also previously served as a director of Genzyme Corporation. Mr. Bertolini has been a director since January 2011.
Mr. Bertolini’s qualifications to serve as a director include his industry and financial expertise. He has extensive experience in building world-class finance and information technology functions and in leading business development and strategy. He has had responsibility for key financial areas including tax, accounting, and financial asset management, and extensive experience in audit, financial controls, and corporate governance. He has expertise in working with small and large health care companies on initial public offerings, licensing, and other strategic issues. As a result of his extensive background in public accounting and prior experience as a public company Chief Financial Officer, Mr. Bertolini qualifies as an “audit committee financial expert” under SEC guidelines.
|
|
|
Name and Age as of the 2023
Annual Meeting |
| | | | |
Position, Principal Occupation, Business Experience and Directorships
|
|
|
Deborah T. Kochevar, D.V.M., Ph.D. (she/her/hers)
|
| |
66
|
| |
Senior Fellow, The Fletcher School of Law and Diplomacy, with a focus on Global One Health and health diplomacy, and Dean Emerita of Cummings School of Veterinary Medicine at Tufts University since 2019. From 2018 until 2019, Dr. Kochevar served as Provost and Senior Vice President ad interim and, from 2006 until 2018, as Dean of Cummings School of Veterinary Medicine at Tufts University. Previously, Dr. Kochevar was a long-time faculty member and administrator at the College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, where she held the Wiley Chair of Veterinary Medical Education. Dr. Kochevar is a past president of the Association of American Veterinary Medical Colleges and American College of Veterinary Clinical Pharmacology. Dr. Kochevar is active in the American Veterinary Medical Association, having chaired its Council on Education and the Educational Commission for Foreign Veterinary Graduates. Dr. Kochevar serves as a director at Elanco Inc. Dr. Kochevar has been a director since October 2008.
Dr. Kochevar was selected to the Board in recognition of her distinct perspective as a highly distinguished academic and educator in the life sciences. As a boarded diplomate of the American College of Veterinary Clinical Pharmacology, with a Ph.D. in cell and molecular biology combined with a D.V.M. degree, and with a deep knowledge base of comparative and translational medicine and complex animal models, Dr. Kochevar’s training and experience is particularly suited to understanding and providing insights into the veterinary medical, contract research and drug development support activities that we conduct. Dr. Kochevar also provides the Board with current industry and scientific insights through her ongoing involvement in biomedical professional and trade organizations and Global OneHealth.
|
|
|
Name and Age as of the 2023
Annual Meeting |
| | | | |
Position, Principal Occupation, Business Experience and Directorships
|
|
|
George Llado, Sr. (he/him/his)
|
| |
57
|
| |
Former Senior Vice President and Chief Information Officer (CIO) of Alexion Pharmaceuticals, Inc. As an industry veteran with over 30 years of pharmaceutical business and technology and cyber-security experience, Mr. Llado, through his time at Alexion, contributed to the development and implementation of innovative technology, enabling data-driven insights across Alexion’s R&D, Commercial, Manufacturing Operations and Supply Chain functions. Prior to joining Alexion, Mr. Llado served as Vice President and business line CIO for Merck and Co., where he led the planning and development of IT solutions for the company’s Manufacturing Division. Before that, he was Merck’s Vice President, IT and business line CIO for the Global Commercial Organization and various corporate G&A functions. He led the large-scale merger integration of Merck and Schering-Plough across the IT and Shared Business Services organizations. He also held several other positions of increasing responsibility at Merck, and previously worked at Citibank, N.A. Mr. Llado serves on the National Center for Women & Information Technology (NCWIT) Board, where he participates on the board’s Development Committee and has sponsored key programs such as “Counselors for Computing” that have advanced the organization’s membership. He also serves on the Temple Fox Business School IT Advisory Board. Mr. Llado has been a director since October 2020.
Mr. Llado was selected to the Board in recognition of his extensive experience as a senior executive at global companies in the pharmaceutical industry, as well as his technology and cyber-security expertise.
|
|
|
Martin W. Mackay, Ph.D. (he/him/his)
|
| |
67
|
| |
Dr. Mackay is co-founder, Chief Executive Officer, and director of Rallybio Corporation, a biotechnology company incorporated in January 2018, which only recently became a public company in July 2021. From May 2013 to June 2017, Dr. Mackay served as the Global Head of Research & Development at Alexion Pharmaceuticals, Inc. and, from July 2010 to January 2013, Dr. Mackay served as the President of R&D at AstraZeneca PLC, where he led the research and development organization and had overall accountability for delivering new products from its pipeline. Dr. Mackay has served as a director of Novo Nordisk since March 2018. From October 2020 through April 2022, Dr. Mackay served as a director of 5:01 Acquisition Corp., a blank check company whose primary purpose was to effect a business combination, and which has never engaged in operating activities. Dr. Mackay has been a director of the Company since July 2017.
Dr. Mackay’s extensive experience leading research and development organizations at both global pharmaceutical and biotechnology companies provides us with a unique combination of expertise.
|
|
|
Name and Age as of the 2023
Annual Meeting |
| | | | |
Position, Principal Occupation, Business Experience and Directorships
|
|
|
George E. Massaro (he/him/his)
|
| |
75
|
| |
Former Director and Vice Chair of Huron Consulting Group, Inc., a management consulting company from 2010 to 2020. Mr. Massaro was non-Executive Chair of the Board of Huron Consulting Group from July 2009 to May 2010, Director and Vice Chair of Huron Consulting Group since June 2004 (Vice Chair since March 2005), Chief Operating Officer of Huron Consulting Group, Inc. and Huron Consulting Services LLC from June 2003 until March 2005, and Managing Director of Huron Consulting Services LLC from August 2002 to May 2003. He was the Managing Partner of Arthur Andersen LLP’s New England practice from 1998 to 2002. Mr. Massaro also served as a director of Eastern Bank Corporation, an independent mutual bank holding company in New England from 2003 through 2017. Mr. Massaro has been a director since 2003.
Mr. Massaro has more than 35 years of accounting and auditing experience with expertise in a broad range of areas. As a former managing partner of a major accounting firm, Mr. Massaro brings a deep knowledge of financial reporting, and auditing and tax matters applicable to a variety of industries. Mr. Massaro also provides business acumen from his numerous senior positions at Huron Consulting, as well as his service on boards of other companies. As a result of his extensive background in public accounting and prior experience at Arthur Andersen, Mr. Massaro qualifies as an “audit committee financial expert” under SEC guidelines.
|
|
|
C. Richard Reese (he/him/his)
|
| |
77
|
| |
Former Chair and Chief Executive Officer of Iron Mountain Incorporated, a global public information protection and storage company. Mr. Reese originally served as the Chief Executive Officer of Iron Mountain from 1981-2008 and then again from 2011-2012 and served as its Chair from 1995-2008 and as Executive Chair between June 2008 and April 2011. Mr. Reese has been a director since 2007.
Mr. Reese is a proven global business leader who, from the time he joined Iron Mountain as its president in 1981 with only $3 million in annual revenue, developed it into a global company with over $3 billion in revenue and more than 100,000 corporate customers. As a member of our Board, Mr. Reese provides us with invaluable guidance and advice, particularly in the areas of strategic execution, customer service, and innovation, drawing upon his extensive experience, entrepreneurial spirit, and proven track record.
|
|
|
Name and Age as of the 2023
Annual Meeting |
| | | | |
Position, Principal Occupation, Business Experience and Directorships
|
|
|
Craig B. Thompson, M.D. (he/him/his)
|
| |
70
|
| |
Former President and Chief Executive Officer of Memorial Sloan-Kettering Cancer Center from 2010 to September 2022. Dr. Thompson continues to oversee a research laboratory at the Sloan Kettering Institute focusing on cellular metabolism and its role in cancer. From 2006 to 2010, Dr. Thompson served as the Director of the Abramson Cancer Center at the University of Pennsylvania School of Medicine, and, from 1999 to 2011, he was a Professor of Medicine and Cancer Biology at the University of Pennsylvania. Dr. Thompson is currently a member of the Board of Directors of Regeneron Pharmaceuticals, Inc., and he previously served on the Board of Directors of Merck & Co. Inc. from 2009 to 2018. He is also a board member of the Howard Hughes Medical Institute, M.D. Anderson Cancer Center, Ohio State University Comprehensive Cancer Center, City of Hope Comprehensive Cancer Center, the Economic Club of New York, and a member of the Albert Lasker Medical Research Awards Prize Committee. Dr. Thompson is an elected member of the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, and the Association of American Physicians. Dr. Thompson holds a number of patents related to immunotherapy and apoptosis and has founded three biotechnology companies, including Agios Pharmaceuticals. Dr. Thompson has been a director since December 2022.
Dr. Thompson was selected to the Board in recognition of his distinct perspective as a highly distinguished academic and educator in medicine as well as his extensive scientific and medical expertise relevant to life science industries, including the research and development activities of our clients. Dr. Thompson’s training and experience is particularly suited to understanding and providing insights into the contract research and drug development support activities we conduct. Dr. Thompson also provides the Board with current industry and medical insights.
|
|
|
Richard F. Wallman
(he/him/his) |
| |
71
|
| |
From 1995 through 2003, Mr. Wallman served as the Senior Vice President and Chief Financial Officer of Honeywell International, Inc., a diversified technology company, and AlliedSignal, Inc. (prior to its merger with Honeywell). He is also a member of the boards of directors of Roper Technologies, Inc., SmileDirectClub, Inc., and CECO Environmental Corp. and in the past five years has served as a member of the boards of Extended Stay America, Boart Longyear Limited, and Wright Medical Group, Inc. Mr. Wallman has been a director since January 2011.
Mr. Wallman’s leadership experience, including his role as a Chief Financial Officer, and his financial and outside board experience, provide him with an informed understanding of the financial issues and risks that affect us.
|
|
|
Name and Age as of the 2023
Annual Meeting |
| | | | |
Position, Principal Occupation, Business Experience and Directorships
|
|
|
Virginia M. Wilson
(she/her/hers) |
| |
68
|
| |
Retired Senior Executive Vice President and Chief Financial Officer of TIAA, where she was responsible for leading finance and actuarial functions. Prior to joining TIAA in 2010, Ms. Wilson served as Executive Vice President and Chief Financial Officer of Wyndham Worldwide Corporation, leading Wyndham’s finance and technology organizations following its spin-off from Cendant Corporation in 2006. Previously, she served as Cendant’s Executive Vice President and Chief Accounting Officer and also served as Senior Vice President and Corporate Controller of both MetLife, Inc. and Transamerica’s life insurance division. Ms. Wilson began her career at Deloitte and is a Certified Public Accountant. She is a former member of the board of directors of Conduent Incorporated. Ms. Wilson has been a director since October 2019.
Ms. Wilson brings to the Board more than 30 years of financial management experience overseeing the accounting, actuarial, tax, and financial planning and reporting functions at large, multinational organizations. In addition, as a result of her background as a Certified Public Accountant and prior service as a public company Chief Financial Officer, Ms. Wilson qualifies as an “audit committee financial expert” under SEC guidelines.
|
|
| | |||||||||||||||||||||||||||||||||
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
|
| | |
James C.
Foster |
| |
Nancy C.
Andrews |
| |
Robert
Bertolini |
| |
Deborah T.
Kochevar |
| |
George
Llado, Sr. |
| |
Martin W.
Mackay |
| |
George E.
Massaro |
| |
C. Richard
Reese |
| |
Craig B.
Thompson |
| |
Richard F.
Wallman |
| |
Virginia M.
Wilson |
|
Public Company
CEO or CFO |
| |
●
|
| | | | |
●
|
| | | | | | | |
●
|
| | | | |
●
|
| | | | |
●
|
| |
●
|
|
Industry*
|
| |
●
|
| | | | |
●
|
| | | | |
●
|
| |
●
|
| | | | | | | | | | | | | | | |
Senior Business
Management |
| |
●
|
| |
●
|
| | | | |
●
|
| |
●
|
| |
●
|
| |
●
|
| |
●
|
| |
●
|
| | | | |
●
|
|
Business Development /
Corporate Strategy |
| |
●
|
| | | | |
●
|
| |
●
|
| | | | |
●
|
| |
●
|
| |
●
|
| | | | |
●
|
| |
●
|
|
Finance / Accounting
|
| | | | | | | |
●
|
| | | | | | | | | | |
●
|
| | | | | | | |
●
|
| |
●
|
|
International
Business Management |
| |
●
|
| | | | | | | |
●
|
| |
●
|
| |
●
|
| |
●
|
| |
●
|
| | | | | | | |
●
|
|
R&D / Scientific
|
| | | | |
●
|
| | | | |
●
|
| | | | |
●
|
| | | | | | | |
●
|
| | | | | | |
Information Technology /
Digital / Cyber |
| | | | | | | | | | | | | |
●
|
| | | | | | | | | | | | | | | | |
●
|
|
ESG
|
| | | | | | | | | | |
●
|
| |
●
|
| | | | | | | | | | |
●
|
| | | | | | |
Human Capital
Management |
| |
●
|
| |
●
|
| | | | |
●
|
| |
●
|
| |
●
|
| | | | | | | | | | | | | | | |
Risk Management
|
| |
●
|
| |
●
|
| |
●
|
| |
●
|
| |
●
|
| |
●
|
| |
●
|
| | | | |
●
|
| |
●
|
| |
●
|
|
Diversity**
|
| | | | |
●
|
| | | | |
●
|
| |
●
|
| | | | | | | | | | | | | | | | |
●
|
|
Military Veteran
|
| | | | | | | | | | | | | | | | | | | | | | |
●
|
| |
●
|
| | | | | | |
|
Tenure
|
| |
Age
|
| ||||||
| Newer Tenured (<5 years) | | |
4
|
| |
<60 years
|
| |
1
|
|
|
Medium Tenured (6-10 years)
|
| |
1
|
| |
60-70 years
|
| |
6
|
|
| Longer Tenured (>10 years) | | |
6
|
| |
>70 years
|
| |
4
|
|
Name
|
| |
Fees Earned or
Paid in Cash ($)(1) |
| |
Stock Awards
($)(2) |
| |
Option Awards
($)(3) |
| |
All Other
Compensation ($)(4) |
| |
Total
($) |
| |||||||||||||||
George E. Massaro . . . . . . . . . . . . .
|
| | | $ | 113,750 | | | | | $ | 127,828 | | | | | $ | 127,098 | | | | | $ | — | | | | | $ | 368,676 | | |
Robert Bertolini . . . . . . . . . . . . . . . .
|
| | | | 88,750 | | | | | | 127,828 | | | | | | 127,098 | | | | | | — | | | | | | 343,676 | | |
Virginia M. Wilson . . . . . . . . . . . . .
|
| | | | 88,750 | | | | | | 127,828 | | | | | | 127,098 | | | | | | — | | | | | | 343,676 | | |
C. Richard Reese . . . . . . . . . . . . . . .
|
| | | | 83,750 | | | | | | 127,828 | | | | | | 127,098 | | | | | | — | | | | | | 338,676 | | |
Nancy C. Andrews . . . . . . . . . . . . . .
|
| | | | 82,500 | | | | | | 127,828 | | | | | | 127,098 | | | | | | — | | | | | | 337,426 | | |
Deborah T. Kochevar . . . . . . . . . . .
|
| | | | 78,750 | | | | | | 127,828 | | | | | | 127,098 | | | | | | — | | | | | | 333,676 | | |
Richard F. Wallman . . . . . . . . . . . .
|
| | | | 78,750 | | | | | | 127,828 | | | | | | 127,098 | | | | | | — | | | | | | 333,676 | | |
Martin Mackay(5). . . . . . . . . . . . . . . .
|
| | | | 86,250 | | | | | | 122,048 | | | | | | 121,474 | | | | | | — | | | | | | 329,772 | | |
George Llado, Sr. . . . . . . . . . . . . . .
|
| | | | 63,750 | | | | | | 127,828 | | | | | | 127,098 | | | | | | — | | | | | | 318,676 | | |
George M. Milne, Jr.(6). . . . . . . . . .
|
| | | | 15,000 | | | | | | — | | | | | | — | | | | | | — | | | | | | 15,000 | | |
Craig B. Thompson(7). . . . . . . . . . .
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | | | | | | | | | | | | | | | | ||||||||||
| | | | | | | | |
✓
Majority voting standard
in uncontested director elections with a mandatory resignation policy that requires incumbent director nominees to submit a resignation that becomes effective upon the failure to receive a majority vote and the Board’s acceptance of the resignation
|
| | |
✓
Expectation of director attendance
with all directors attending over 75% of Board and respective Committee meetings in 2022
|
| | | | | | ||||||||||
| | | | | | | | |
✓
Mandatory director retirement age
of 75 with grandfather provision permitting any director who was a member of the Board as of December 17, 2019, such as Mr. Reese, to retire at age 78
|
| | |
✓
Proxy Access
provision in our by-laws by which eligible stockholders may nominate director candidates for inclusion in our proxy statement and proxy card
|
| | | | | | ||||||||||
| | | | | | | | |
✓
Annual director and committee assessments
to ensure that the Board and its Committees are performing effectively and in the best interests of the Company and its stockholders
|
| | |
✓
Commitment to ESG principles
through which we strive to promote and support business practices that are environmentally sustainable, socially conscious and aligned with strong corporate governance practices, including Board oversight of ESG risk
|
| | | | | | ||||||||||
| | | | | | | | |
✓
Lead Independent Director
to provide independent oversight and is responsible for ensuring that the Board is acting in conformity with good corporate governance practices and in our long-term best interests
|
| | |
✓
Code of Business Conduct and Ethics
that outlines the key laws and policies that apply to our business, as well as an individual’s responsibilities for maintaining a positive and ethical work environment and our resources for issues involving legal compliance or ethical business conduct
|
| | | | | | ||||||||||
| | | | | | | | |
✓
Independent Board Committee Chairs
to provide independent oversight of each Committee
|
| | |
✓
Information security risk oversight
by Board (Audit Committee)
|
| | | | | | ||||||||||
| | | | | | | | |
✓
Corporate strategy and risk oversight
by Board, which oversees the process and performs this oversight role using several different levels of review
|
| | |
✓
Political Contribution Policy
that, among other things, prohibits the use of Company resources: to fund or support political parties, officials or candidates without prior approval from CEO, CFO and General Counsel; and for employees’ personal political activities
|
| | | | | | ||||||||||
| | | | | | | | | | | | |
✓
Stock Ownership Requirements
require our officers and directors to hold shares as follows:
|
| | | |||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | ||
| | | | | | | | | | | | |
Position
|
| | |
Stock Ownership Requirement
|
| | | | | | | | | | ||
| | | | | | | | | | | | |
Director
|
| | |
5x cash retainer
|
| | | |||||||||
| | | | | | | | | | | | |
CEO
|
| | |
6x base salary
|
| | | |||||||||
| | | | | | | | | | | | |
Direct Reports to CEO
|
| | |
3x base salary
|
| | | |||||||||
| | | | | | | | | | | | |
Senior Vice President
(not reporting to CEO) |
| | |
2x base salary
|
| | | |||||||||
| | | | | | | | | | | | |
Vice President
|
| | |
1x base salary
|
| | | | | |||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | |
Name of Beneficial Owner
|
| |
Number of Shares
Beneficially Owned as of March 16, 2023 |
| |
Percentage
of Shares Outstanding |
| ||||||
5% Shareholders | | | | | | | | | | | | | |
The Vanguard Group, Inc.
|
| | | | 5,956,960(1) | | | | | | 11.6% | | |
BlackRock, Inc.
|
| | | | 4,981,145(2) | | | | | | 9.7% | | |
Named Executives | | | | | | | | | | | | | |
James C. Foster
|
| | | | 283,077(3) | | | | | | * | | |
Flavia H. Pease
|
| | | | 0(4) | | | | | | * | | |
William D. Barbo
|
| | | | 32,157(5) | | | | | | | | |
Birgit Girshick
|
| | | | 46,018(6) | | | | | | * | | |
Joseph W. LaPlume
|
| | | | 28,396(7) | | | | | | * | | |
David R. Smith
|
| | | | 31,485(8) | | | | | | | | |
Non-Employee Directors | | | | | | | | | | | | | |
Nancy C. Andrews
|
| | | | 7,640(9) | | | | | | | | |
Robert Bertolini
|
| | | | 35,989(10) | | | | | | * | | |
Deborah T. Kochevar
|
| | | | 9,404(11) | | | | | | * | | |
George Llado, Sr.
|
| | | | 5,544(12) | | | | | | | | |
Martin W. Mackay
|
| | | | 15,705(13) | | | | | | * | | |
George E. Massaro
|
| | | | 7,985(14) | | | | | | * | | |
C. Richard Reese
|
| | | | 69,707(15) | | | | | | * | | |
Craig B. Thompson
|
| | | | 0(16) | | | | | | | | |
Richard F. Wallman
|
| | | | 27,136(17) | | | | | | * | | |
Virginia M. Wilson
|
| | | | 8,014(18) | | | | | | * | | |
All current executive officers and directors as a group (18 persons)
|
| | | | 668,885(19) | | | | | | 1.3% | | |
Plan Category
|
| |
Number of
securities to be issued upon exercise of outstanding options, warrants and rights |
| |
Weighted
average exercise price of outstanding options, warrants and rights |
| |
Number of securities
remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) |
| |||||||||
| | |
(a)
|
| |
(b)
|
| |
(c)
|
| |||||||||
Equity compensation plan approved by security holders: | | | | | | | | | | | | | | | | | | | |
2016 Incentive Plan
|
| | | | 88,989 | | | | | $ | 109.34 | | | | | | 0 | | |
2018 Incentive Plan
|
| | | | 793,241 | | | | | $ | 215.06 | | | | | | 5,118,803 | | |
Equity compensation plans not approved by security holders
|
| | | | — | | | | | | — | | | | | | — | | |
Total
|
| | | | 882,230(1) | | | | | | | | | | | | 5,118,803(2) | | |
Category
|
| |
Number of
securities outstanding |
| |
Weighted
average exercise price |
| |
Weighted
average term |
| |||||||||
| | |
(a)
|
| |
(b)
|
| |
(c)
|
| |||||||||
Total number of restricted stock/units outstanding(1)
|
| | | | 639,951 | | | | | $ | — | | | | | | — | | |
Total number of options outstanding(2)
|
| | | | 882,230 | | | | | $ | 204.41 | | | | | | 5.7 | | |
Total number of performance share units outstanding(3)
|
| | | | 222,285 | | | | | $ | — | | | | | | — | | |
| | |
Fiscal Year
|
| |||||||||||||||||||||||||||||||||
| | |
2017
|
| |
2018
|
| |
2019
|
| |
2020
|
| |
2021
|
| |
2022
|
| ||||||||||||||||||
Charles River Laboratories International, Inc.
|
| | | $ | 100.00 | | | | | $ | 102.07 | | | | | $ | 138.81 | | | | | $ | 229.98 | | | | | $ | 337.32 | | | | | $ | 199.09 | | |
FY2022 rTSR Peer Group Median
|
| | | | 100.00 | | | | | | 102.84 | | | | | | 133.61 | | | | | | 156.45 | | | | | | 180.65 | | | | | | 177.33 | | |
S&P 500 Health Care
|
| | | | 100.00 | | | | | | 105.01 | | | | | | 129.09 | | | | | | 143.22 | | | | | | 181.99 | | | | | | 180.47 | | |
| |
Core Elements
|
| | |
Supplemental Elements
|
| |
| |
•
Base Salary
•
Annual Cash Incentive Awards (EICP Plan)
•
Long-Term Equity Incentive Awards
|
| | |
•
Deferred Compensation Plan
•
Termination and Change in Control Agreements
•
Retirement Plan
|
| |
| |
2022 Targeted Compensation Mix for Named Executives(1)
|
| | ||||||||||||||||||||||||||||||||
| | | | | |
Core
Compensation Element |
| | |
Foster
|
| | |
Pease(2)
|
| | |
Smith(3)
|
| | |
Barbo
|
| | |
Girshick
|
| | |
LaPlume
|
| | |
Average
|
| |
| |
“Fixed”
Compensation |
| | |
Base
Salary |
| | |
10.3%
|
| | |
19.9%
|
| | |
23.4%
|
| | |
19.9%
|
| | |
15.6%
|
| | |
17.9%
|
| | |
17.8%
|
| |
| |
“At-Risk”
Compensation Elements |
| | |
Annual Cash
Incentive Awards |
| | |
10.3%
|
| | |
13.9%
|
| | |
16.3%
|
| | |
14.0%
|
| | |
12.5%
|
| | |
12.5%
|
| | |
13.3%
|
| |
|
Long-Term
Equity Incentive Awards |
| | |
79.4%
|
| | |
66.2%
|
| | |
60.3%
|
| | |
66.1%
|
| | |
71.9%
|
| | |
69.6%
|
| | |
68.9%
|
| |
| | Abbott Laboratories | | | | Gilead Sciences, Inc. | | | | Pfizer Inc. | | |
| | Agilent Technologies, Inc.* | | | | Hologic Inc. | | | | PPD, Inc.* | | |
| | Amgen Inc. | | | | Icon plc | | | | Quest Diagnostics Incorporated | | |
| | Baxter International Inc.* | | | | IDEXX Laboratories Inc.* | | | | Regeneron Pharmaceuticals, Inc.* | | |
| |
Becton, Dickinson and Company*
|
| | | Illumina, Inc.* | | | | STERIS plc* | | |
| | Bio-Rad Laboratories, Inc.* | | | | IQVIA Holdings Inc.* | | | | Syneos Health, Inc.* | | |
| | Biogen Inc.* | | | |
Laboratory Corporation of America Holdings*
|
| | | Teleflex Incorporated* | | |
| | Boston Scientific Corporation* | | | | Medpace Holdings, Inc. | | | | Thermo Fisher Scientific Inc. | | |
| | Bristol-Myers Squibb Company | | | | Medtronic, Inc. | | | |
Vertex Pharmaceuticals Incorporated*
|
| |
| | Bruker Corporation* | | | | Merck & Co., Inc. | | | | Waters Corporation* | | |
| | Catalent, Inc.* | | | | Mettler Toledo International Inc. | | | | West Pharmaceutical Services | | |
| | Eli Lilly and Company | | | | Myriad Genetics, Inc.* | | | | | | |
| | Endo International plc | | | | PerkinElmer, Inc.* | | | | | | |
Name
|
| |
2022 Salary
|
| |||
James C. Foster
|
| | | $ | 1,412,291 | | |
Flavia H. Pease
|
| | | $ | 600,000 | | |
William D. Barbo
|
| | | $ | 550,050 | | |
Birgit Girshick
|
| | | $ | 650,000 | | |
Joseph W. LaPlume
|
| | | $ | 520,000 | | |
David R. Smith(1)
|
| | | $ | 580,681 | | |
| |
Named Executive
|
| | |
Target %
(of base salary) |
| | |
Target
EICP Award Amount |
| | |
Actual
EICP Award Amount |
| | |
Performance
Goal |
| | |
Weighting
|
| | |
Target
|
| | |
Actual
|
| | ||||||||||||
| |
James C. Foster
|
| | | | |
100%
|
| | | | | $ |
1,412,291
|
| | | | | $ |
1,030,973
|
| | | |
1.
CRL Revenue(1)
2.
CRL OI(2)
|
| | |
50%
50%
|
| | |
$4,105 million
$870.6 million
|
| | |
$3,976 million
$834.0 million
|
| | |||
| |
Flavia H. Pease(3)
|
| | | | | 70% | | | | | | $ | 288,822 | | | | | | $ | 159,430 | | | | |
1.
CRL Revenue(1)
2.
CRL OI(2)
3.
CRL FCF(6)
|
| | |
25%
50%
25%
|
| | |
$4,105 million
$870.6 million
$442.1 million
|
| | |
$3,976 million
$834.0 million
$330.0 million
|
| | |||
| |
William D. Barbo
|
| | | | | 70% | | | | | | $ | 385,035 | | | | | | $ | 278,303 | | | | |
1.
CRL Revenue(1)
2.
CRL OI(2)
|
| | |
70%
30%
|
| | |
$4,105 million
$870.6 million
|
| | |
$3,976 million
$834.0 million
|
| | |||
| |
Birgit Girshick
|
| | | | | 80% | | | | | | $ | 520,000 | | | | | | $ | 379,600 | | | | |
1.
CRL Revenue(1)
2.
CRL OI(2)
|
| | | | |
50%
50% |
| | | |
$4,105 million
$870.6 million
|
| | |
$3,976 million
$834.0 million
|
| |
| |
Joseph W. LaPlume
|
| | | | | 70% | | | | | | $ | 364,000 | | | | | | $ | 265,720 | | | | |
1.
CRL Revenue(1)
2.
CRL OI(2)
|
| | | | |
50%
50% |
| | | |
$4,105million
$870.6 million
|
| | |
$3,976 million
$834.0 million
|
| |
| |
David R. Smith(4)(5)
|
| | | | | 70% | | | | | | $ | 304,022 | | | | | | $ | 167,820 | | | | |
1.
CRL Revenue(1)
2.
CRL OI(2)
3.
CRL FCF(6)
|
| | | | |
25%
50% 25% |
| | | |
$4,105 million
$870.6 million
$442.1 million
|
| | |
$3,976 million
$834.0 million
$330.0 million
|
| |
Name
|
| |
Actual %
of Cash Incentive Award vs. Target 2015 |
| |
Actual %
of Cash Incentive Award vs. Target - 2016 |
| |
Actual %
of Cash Incentive Award vs. Target - 2017 |
| |
Actual %
of Cash Incentive Award vs. Target - 2018 |
| |
Actual %
of Cash Incentive Award vs. Target - 2019 |
| |
Actual %
of Cash Incentive Award vs. Target - 2020 |
| |
2021 Cash
Incentive Award |
| |
Actual %
of Cash Incentive Award vs. Target - 2021 |
| |
2022 Cash
Incentive Award |
| |
Actual %
of Cash Incentive Award vs. Target - 2022 |
| ||||||||||||||||||||||||||||||
James C. Foster
|
| | | | 156.6% | | | | | | 152.5% | | | | | | 102.7% | | | | | | 188.7% | | | | | | 141.5% | | | | | | 108.0% | | | | | $ | 1,871,457 | | | | | | 137.2% | | | | | $ | 1,030,973 | | | | | | 73.0% | | |
Flavia H. Pease
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 159,430 | | | | | | 55.2% | | |
William D. Barbo
|
| | | | — | | | | | | 130.3% | | | | | | 121.4% | | | | | | 141.0% | | | | | | 104.2% | | | | | | 108.0% | | | | | | 503,947 | | | | | | 134.8% | | | | | | 278,303 | | | | | | 72.3% | | |
Birgit Girshick
|
| | | | — | | | | | | — | | | | | | — | | | | | | 168.8% | | | | | | 129.7% | | | | | | 108.0% | | | | | | 579,716 | | | | | | 127.4% | | | | | | 379,600 | | | | | | 73.0% | | |
Joseph W. LaPlume
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 120.6% | | | | | | 108.0% | | | | | | 480,025 | | | | | | 137.2% | | | | | | 265,720 | | | | | | 73.0% | | |
David R. Smith(1)
|
| | | | 81.4% | | | | | | 156.7% | | | | | | 99.3% | | | | | | 192.5% | | | | | | 149.9% | | | | | | 108.0% | | | | | | 674,799 | | | | | | 154.3% | | | | | | 167,820 | | | | | | 55.2% | | |
| |
2022 PSU Grant
Base Award Calculation |
| | |
Future Final Award Levels (as % of Target Award)
|
| | ||||||||||||||||||||||||||||||||||||||
|
rTSR
≤30th percentile |
| | |
rTSR =
55th percentile |
| | |
rTSR
≥75th percentile |
| | |||||||||||||||||||||||||||||||||||
| |
Target
Non-GAAP EPS* |
| | |
Actual
Non-GAAP EPS |
| | |
Actual Non-GAAP
EPS as % of Target |
| | |
Base Award
(as % of Target Award) |
| | |
Minimum
(Base Award × 65%) |
| | |
Target
(Base Award × 100%) |
| | |
Maximum
(Base Award × 135%) |
| | ||||||||||||||||||
| |
$11.76
|
| | | | $ | 11.12 | | | | | | | 94.6% | | | | | | | 72.5% | | | | | | | 47.1% | | | | | | | 72.5% | | | | | | | 97.9% | | | |
| |
2020 PSU Grant Base
Award Calculation |
| | |
Final Award Levels
|
| | |||||||||||||||||||||||||||||||
|
rTSR =
64th percentile |
| | ||||||||||||||||||||||||||||||||||||
| |
Target
Non-GAAP EPS |
| | |
Actual
Non-GAAP EPS |
| | |
Actual Non-GAAP
EPS as % of Target |
| | |
Base Award
(as % of Target Award) * |
| | |
rTSR
Adjustment |
| | |
Final Award
(as % of Target Award) |
| | |||||||||||||||
| |
$7.86
|
| | | | $ | 8.13 | | | | | | | 103.4% | | | | | | | 150% | | | | | | | 114% | | | | | | | 171% | | | |
|
CEO
|
| | 6 times base salary | |
|
Direct reports to the CEO
|
| | 3 times base salary | |
|
Senior Vice President (not reporting to the CEO)
|
| | 2 times base salary | |
|
Vice President
|
| | 1 time base salary | |
Name and Principal Position(1)
|
| |
Year
|
| |
Salary
($) |
| |
Stock
Awards ($)(2) |
| |
Option
Awards ($)(3) |
| |
Bonus ($)
|
| |
Non-Equity
Incentive Plan Compensation ($)(4) |
| |
Change in
Pension Value and Non-qualified Deferred Compensation ($)(5) Earnings ($)(5) |
| |
All Other
Compensation ($)(6) |
| |
Total
($) |
| |||||||||||||||||||||||||||
James C. Foster
Chairman, President, Chief Executive Officer and Director |
| | | | 2022 | | | | | | 1,399,442 | | | | | | 8,759,995 | | | | | | 2,179,888 | | | | | | 0 | | | | | | 1,030,973 | | | | | | 0 | | | | | | 77,574 | | | | | | 13,447,872 | | |
| | | 2021 | | | | | | 1,353,841 | | | | | | 8,359,896 | | | | | | 2,062,193 | | | | | | 0 | | | | | | 1,871,457 | | | | | | 0 | | | | | | 58,194 | | | | | | 13,705,581 | | | ||
| | | 2020 | | | | | | 1,354,971 | | | | | | 8,160,030 | | | | | | 2,058,396 | | | | | | 0 | | | | | | 1,430,772 | | | | | | 194,061 | | | | | | 285,181 | | | | | | 13,483,411 | | | ||
Flavia H. Pease(7)
Corporate Executive Vice President and Chief Financial Officer |
| | | | 2022 | | | | | | 403,844 | | | | | | 2,883,429 | | | | | | 828,323 | | | | | | 200,000(7) | | | | | | 159,430 | | | | | | 0 | | | | | | 9,124 | | | | | | 4,484,150 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||
William D. Barbo
Corporate Executive Vice President, Chief Commercial Officer |
| | | | 2022 | | | | | | 545,738 | | | | | | 1,467,715 | | | | | | 365,944 | | | | | | 0 | | | | | | 278,303 | | | | | | 0 | | | | | | 104,508 | | | | | | 2,762,209 | | |
| | | 2021 | | | | | | 527,176 | | | | | | 1,373,282 | | | | | | 339,892 | | | | | | 0 | | | | | | 503,947 | | | | | | 0 | | | | | | 101,922 | | | | | | 2,846,219 | | | ||
| | | 2020 | | | | | | 515,126 | | | | | | 1,289,517 | | | | | | 325,281 | | | | | | 0 | | | | | | 384,501 | | | | | | 0 | | | | | | 95,050 | | | | | | 2,609,475 | | | ||
Birgit Girshick
Corporate Executive Vice President, Chief Operating Officer |
| | | | 2022 | | | | | | 650,000 | | | | | | 2,412,795 | | | | | | 601,505 | | | | | | 0 | | | | | | 379,600 | | | | | | 0 | | | | | | 121,630 | | | | | | 4,165,529 | | |
| | | 2021 | | | | | | 502,351 | | | | | | 1,615,375 | | | | | | 399,892 | | | | | | 0 | | | | | | 579,716 | | | | | | 0 | | | | | | 99,340 | | | | | | 3,196,674 | | | ||
| | | 2020 | | | | | | 475,329 | | | | | | 1,384,280 | | | | | | 349,245 | | | | | | 0 | | | | | | 352,218 | | | | | | 0 | | | | | | 85,372 | | | | | | 2,646,443 | | | ||
Joseph LaPlume
Corporate Executive Vice President Corporate Development and Strategy |
| | | | 2022 | | | | | | 514,613 | | | | | | 1,628,579 | | | | | | 406,020 | | | | | | 0 | | | | | | 265,720 | | | | | | 0 | | | | | | 91,013 | | | | | | 2,905,945 | | |
| | | 2021 | | | | | | 494,323 | | | | | | 6,467,972 | | | | | | 379,892 | | | | | | 0 | | | | | | 480,025 | | | | | | 0 | | | | | | 95,488 | | | | | | 7,917,700 | | | ||
| | | 2020 | | | | | | 489,858 | | | | | | 1,423,904 | | | | | | 359,185 | | | | | | 0 | | | | | | 362,086 | | | | | | 0 | | | | | | 89,833 | | | | | | 2,724,866 | | | ||
David R. Smith(8)
Former Corporate Executive Vice President and Chief Financial Officer |
| | | | 2022 | | | | | | 441,496 | | | | | | 1,500,056 | | | | | | 0 | | | | | | 0 | | | | | | 167,820 | | | | | | 0 | | | | | | 63,042 | | | | | | 2,172,415 | | |
| | | 2021 | | | | | | 618,163 | | | | | | 1,792,243 | | | | | | 443,499 | | | | | | 0 | | | | | | 674,799 | | | | | | 0 | | | | | | 82,324 | | | | | | 3,611,028 | | | ||
| | | 2020 | | | | | | 599,152 | | | | | | 1,546,432 | | | | | | 390,134 | | | | | | 0 | | | | | | 463,595 | | | | | | 0 | | | | | | 114,250 | | | | | | 3,113,563 | | |
| |
Name
|
| | |
Type of
Award(*) |
| | |
Grant
Date |
| | |
Date of
Board or Compensation Committee Action to Approve Grant(1) |
| | |
Estimated Possible
Payouts Under Non-Equity Incentive Plan Awards(2) |
| | |
Estimated Possible
Payouts Under Equity Incentive Plan Awards(3) |
| | |
All
Other Stock Awards: Number of Shares of Stock or Units (#)(4) |
| | |
All
Other Option Awards: Number of Securities Underlying Options (#)(5) |
| | |
Exercise
or Base Price of Option Awards ($/Sh) |
| | |
Grant
Date Fair Value of Stock and Option Awards ($)(6) |
| | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Threshold
($) |
| | |
Target
($) |
| | |
Maximum
($) |
| | |
Threshold
(#) |
| | |
Target
(#) |
| | |
Maximum
(#) |
| | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |
James C. Foster
|
| | | | | EICP | | | | | | | 1/27/2022 | | | | | | | 1/27/2022 | | | | | | $ | 141,229 | | | | | | $ | 1,412,291 | | | | | | $ | 2,824,583 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | SO | | | | | | | 5/27/2022 | | | | | | | 1/27/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 24,042 | | | | | | | 244.41 | | | | | | $ | 2,179,888 | | | | |||||
| | | PSU | | | | | | | 5/27/2022 | | | | | | | 1/27/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | 13,530 | | | | | | | 41,631 | | | | | | | 83,262 | | | | | | | | | | | | | | | | | | | | | | | | | | | $ | 8,759,995 | | | | |||||
| |
Flavia H. Pease (7)
|
| | | | | EICP | | | | | | | 3/4/2022 | | | | | | | 3/4/2022 | | | | | | $ | 28,882 | | | | | | $ | 288,822 | | | | | | $ | 577,644 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | SO | | | | | | | 5/02/2022 | | | | | | | 3/4/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 4,649 | | | | | | | 245.88 | | | | | | $ | 427,290 | | | | |||||
| | | RSU | | | | | | | 5/02/2022 | | | | | | | 3/4/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 5,185 | | | | | | | | | | | | | | | | | | | | $ | 1,274,888 | | | | |||||
| | | SO | | | | | | | 5/27/2022 | | | | | | | 3/4/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 4,423 | | | | | | | 244.41 | | | | | | $ | 401,033 | | | | |||||
| | | RSU | | | | | | | 5/27/2022 | | | | | | | 3/4/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,637 | | | | | | | | | | | | | | | | | | | | $ | 400,099 | | | | |||||
| | | PSU | | | | | | | 5/27/2022 | | | | | | | 3/4/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,866 | | | | | | | 5,743 | | | | | | | 11,486 | | | | | | | | | | | | | | | | | | | | | | | | | | | $ | 1,208,442 | | | | |||||
| |
William D. Barbo . .
|
| | | | | EICP | | | | | | | 1/27/22 | | | | | | | 1/27/2022 | | | | | | $ | 38,504 | | | | | | $ | 385,035 | | | | | | $ | 770,070 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | SO | | | | | | | 5/27/2022 | | | | | | | 1/27/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 4,036 | | | | | | | 244.41 | | | | | | $ | 365,944 | | | | |||||
| | | RSU | | | | | | | 5/27/2022 | | | | | | | 1/27/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,493 | | | | | | | | | | | | | | | | | | | | $ | 364,904 | | | | |||||
| | | PSU | | | | | | | 5/27/2022 | | | | | | | 1/27/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,703 | | | | | | | 5,241 | | | | | | | 10,482 | | | | | | | | | | | | | | | | | | | | | | | | | | | $ | 1,102,811 | | | | |||||
| |
Birgit Girshick . . . .
|
| | | | | EICP | | | | | | | 1/27/22 | | | | | | | 1/27/2022 | | | | | | $ | 52,000 | | | | | | $ | 520,000 | | | | | | $ | 1,040,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | SO | | | | | | | 5/27/2022 | | | | | | | 1/27/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 6,634 | | | | | | | 244.41 | | | | | | $ | 601,505 | | | | |||||
| | | RSU | | | | | | | 5/27/2022 | | | | | | | 1/27/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2,455 | | | | | | | | | | | | | | | | | | | | $ | 600,027 | | | | |||||
| | | PSU | | | | | | | 5/27/2022 | | | | | | | 1/27/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2,800 | | | | | | | 8,615 | | | | | | | 17,230 | | | | | | | | | | | | | | | | | | | | | | | | | | | $ | 1,812,768 | | | | |||||
| |
Joseph LaPlume . . .
|
| | | | | EICP | | | | | | | 1/27/22 | | | | | | | 1/27/2022 | | | | | | $ | 36,400 | | | | | | $ | 364,000 | | | | | | $ | 728,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | SO | | | | | | | 5/27/2022 | | | | | | | 1/27/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 4,478 | | | | | | | 244.41 | | | | | | $ | 406,020 | | | | |||||
| | | RSU | | | | | | | 5/27/2022 | | | | | | | 1/27/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,657 | | | | | | | | | | | | | | | | | | | | $ | 404,987 | | | | |||||
| | | PSU | | | | | | | 5/27/2022 | | | | | | | 1/27/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,890 | | | | | | | 5,815 | | | | | | | 11,630 | | | | | | | | | | | | | | | | | | | | | | | | | | | $ | 1,223,592 | | | | |||||
| |
David R. Smith(8) .
|
| | | | | EICP | | | | | | | 1/27/22 | | | | | | | 1/27/2022 | | | | | | $ | 30,402 | | | | | | $ | 304,022 | | | | | | $ | 608,044 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | RSU | | | | | | | 2/28/2022 | | | | | | | 1/27/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 5,152 | | | | | | | | | | | | | | | | | | | | $ | 1,500,056 | | | |
| | | | | |
Option Awards
|
| | |
Stock Awards
|
| | ||||||||||||||||||||||||||||||||||||||||||||||||
| |
Name
|
| | |
Number of
Securities Underlying Unexercised Options (#) Exercisable |
| | |
Number of
Securities Underlying Unexercised Options (#) Unexercisable |
| | |
Option
Exercise Price ($) |
| | |
Option
Expiration Date |
| | |
Number of
Shares or Units of Stock That Have Not Vested (#) |
| | |
Market
Value of Shares or Units of Stock That Have Not Vested ($)(1) |
| | |
Equity
Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#)(2) |
| | |
Equity
Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($)(1) |
| | ||||||||||||||||||||||||
| |
James C. Foster
|
| | | | | 0 | | | | | | | 17,436(3) | | | | | | | 144.67 | | | | | | | 2/22/2024 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 9,578 | | | | | | | 19,155(4) | | | | | | | 179.66 | | | | | | | 5/29/2030 | | | | | | | | | | | | | | | | | | | | | | | | | | |||||||||||
| | | 4,717 | | | | | | | 14,152(5) | | | | | | | 337.99 | | | | | | | 5/28/2031 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||
| | | 0 | | | | | | | 24,042(7) | | | | | | | 244.41 | | | | | | | 5/27/2032 | | | | | | | 9,832(8) | | | | | | | 2,142,393 | | | | | | | 82,635 | | | | | | | 18,006,167 | | | | |||||
| |
Flavia H. Pease
|
| | | | | 0 | | | | | | | 4,649(6) | | | | | | | 245.88 | | | | | | | 05/02/2032 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 0 | | | | | | | 4,423(7) | | | | | | | 244.41 | | | | | | | 05/27/2032 | | | | | | | 6,822(13) | | | | | | | 1,486,514 | | | | | | | 5,743 | | | | | | | 1,251,400 | | | | |||||
| |
William D. Barbo
|
| | | | | 2,755 | | | | | | | 2,756(3) | | | | | | | 144.67 | | | | | | | 2/22/2024 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 1,514 | | | | | | | 3,027(4) | | | | | | | 179.66 | | | | | | | 5/29/2030 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||
| | | 777 | | | | | | | 2,333(5) | | | | | | | 337.99 | | | | | | | 5/28/2031 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||
| | | 0 | | | | | | | 4,036(7) | | | | | | | 244.41 | | | | | | | 5/27/2032 | | | | | | | 3,803(10) | | | | | | | 828,674 | | | | | | | 10,309 | | | | | | | 2,246,331 | | | | |||||
| |
Birgit Girshick
|
| | | | | 3,205 | | | | | | | 0 | | | | | | | 109.34 | | | | | | | 2/23/2023 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 2,958 | | | | | | | 2.958(3) | | | | | | | 144.67 | | | | | | | 2/22/2024 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||
| | | 3,250 | | | | | | | 3,250(4) | | | | | | | 179.66 | | | | | | | 5/29/2030 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||
| | | 914 | | | | | | | 2,745(5) | | | | | | | 337.99 | | | | | | | 5/28/2031 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||
| | | 0 | | | | | | | 6,634(7) | | | | | | | 244.41 | | | | | | | 5/27/2032 | | | | | | | 5,011(11) | | | | | | | 1,091,897 | | | | | | | 14,577 | | | | | | | 3,176,328 | | | | |||||
| |
Joseph LaPlume
|
| | | | | 6,085 | | | | | | | 3,043(3) | | | | | | | 144.67 | | | | | | | 2/22/2024 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 3,342 | | | | | | | 3,343(4) | | | | | | | 179.66 | | | | | | | 5/29/2030 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||
| | | 869 | | | | | | | 2,607(5) | | | | | | | 337.99 | | | | | | | 5/28/2031 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||
| | | 0 | | | | | | | 4,478(7) | | | | | | | 244.41 | | | | | | | 5/27/2032 | | | | | | | 4,216(12) | | | | | | | 918,666 | | | | | | | 21,671 | | | | | | | 4,722,111 | | | | |||||
| |
David R. Smith
|
| | | | | 0 | | | | | | | 3,305(3) | | | | | | | 144.67 | | | | | | | 2/22/2024 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 1,815 | | | | | | | 3,631(4) | | | | | | | 179.66 | | | | | | | 5/29/2030 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||
| | | 1,014 | | | | | | | 3,044(5) | | | | | | | 337.99 | | | | | | | 5/28/2031 | | | | | | | 8,000(9) | | | | | | | 1,743,200 | | | | | | | 6,614 | | | | | | | 1,441,191 | | | |
| | |
Option Awards
|
| |
Stock Awards
|
| ||||||||||||||||||
Name
|
| |
Number of Shares
Acquired on Exercise (#) |
| |
Value Realized
on Exercise ($)(1) |
| |
Number of Shares
Acquired on Vesting (#) |
| |
Value Realized
on Vesting ($)(2) |
| ||||||||||||
James C. Foster
|
| | | | 37,732 | | | | | | 6,133,567 | | | | | | 61,181 | | | | | | 14,039,302 | | |
Flavia H. Pease
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
William D. Barbo
|
| | | | 3,205 | | | | | | 354,379 | | | | | | 9,918 | | | | | | 2,279,623 | | |
Birgit Girshick
|
| | | | — | | | | | | — | | | | | | 10,621 | | | | | | 2,438,482 | | |
Joseph LaPlume
|
| | | | 7,152 | | | | | | 887,843 | | | | | | 10,881 | | | | | | 2,496,575 | | |
David R. Smith
|
| | | | 8,965 | | | | | | 1,308,327 | | | | | | 11,922 | | | | | | 2,740,667 | | |
Name
|
| |
Executive
Contributions in Last FY ($) |
| |
Registrant
Contributions in Last FY ($)(1)(2) |
| |
Aggregate Earnings
in Last FY ($) |
| |
Aggregate
Withdrawals/ Distributions ($) |
| |
Aggregate Balance
at Last FYE ($)(1) |
| |||||||||||||||
James C. Foster
|
| | | | — | | | | | | — | | | | | | (7,841,125) | | | | | | — | | | | | | 30,149,684 | | |
Flavia H. Pease
|
| | | | 184,614 | | | | | | — | | | | | | 584 | | | | | | — | | | | | | 185,199 | | |
William D. Barbo
|
| | | | — | | | | | | 89,078 | | | | | | (170,093) | | | | | | — | | | | | | 889,687 | | |
Birgit Girshick
|
| | | | — | | | | | | 83,046 | | | | | | (211,640) | | | | | | — | | | | | | 1,113,694 | | |
Joseph LaPlume
|
| | |
|
—
|
| | | | | 82,932 | | | | | | (140,880) | | | | | | — | | | | | | 555,017 | | |
David R. Smith(3)
|
| | | | — | | | | | | — | | | | | | (84,065) | | | | | | — | | | | | | 435,135 | | |
| | | | | | | | | | ||||||||||||
| | | | | | | |
Years of Completed Company Service at Separation Date
|
| | | | | ||||||||
| | | | | | | |
Less than 2 years
|
| | |
2 years to 5 years
|
| | |
5 years or more
|
| | | | |
| | | |
Level:
|
| | |
Amount of Base Salary Pay Continuations:
|
| | | | | ||||||||
| | | | Executive Vice President and above | | | | One year | | | | One year; additional 12 months mitigated severance | | | | Two years | | | | | |
| | | | Senior Vice President | | | | Six months | | | | One year | | | | One year; additional 12 months mitigated | | | | | |
| | | | Vice President | | | | Six months | | | | Six months; additional six months mitigated severance | | | | One year | | | | | |
| |
Name
|
| | |
Cash
Severance |
| | |
Benefits and
Supplemental Perquisites Continuation |
| | |
Equity
Value(1) |
| | |
Retirement Plan
Benefits |
| | |
Other(2)
|
| | |
Accrued
Vacation |
| | |
Total
|
| | |||||||||||||||||||||
| |
James C. Foster(3)
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| |
Voluntary Termination or For Cause Termination
|
| | | | $ | 0 | | | | | | $ | 0 | | | | | | $ | 0 | | | | | | $ | 30,149,684 | | | | | | $ | 0 | | | | | | $ | 54,319 | | | | | | $ | 30,204,003 | | | |
| |
Retirement
|
| | | | $ | 0 | | | | | | $ | 0 | | | | | | $ | 18,397,686 | | | | | | $ | 30,149,684 | | | | | | $ | 0 | | | | | | $ | 54,319 | | | | | | $ | 48,601,689 | | | |
| |
Death
|
| | | | $ | 0 | | | | | | $ | 0 | | | | | | $ | 5,433,384 | | | | | | $ | 30,149,684 | | | | | | $ | 0 | | | | | | $ | 54,319 | | | | | | $ | 35,637,387 | | | |
| |
Disability
|
| | | | $ | 0 | | | | | | $ | 0 | | | | | | $ | 3,449,715 | | | | | | $ | 30,149,684 | | | | | | $ | 0 | | | | | | $ | 54,319 | | | | | | $ | 33,653,718 | | | |
| |
Involuntary Termination—Not For Cause or Good
Reason Termination |
| | | | $ | 2,824,583 | | | | | | $ | 42,140 | | | | | | $ | 0 | | | | | | $ | 30,149,684 | | | | | | $ | 75,000 | | | | | | $ | 54,319 | | | | | | $ | 33,145,726 | | | |
| |
Flavia H. Pease
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Voluntary Termination, Retirement, or For Cause Termination | | | | | $ | 0 | | | | | | $ | 0 | | | | | | $ | 0 | | | | | | $ | 185,199 | | | | | | $ | 0 | | | | | | $ | 23,077 | | | | | | $ | 208,275 | | | |
| |
Death
|
| | | | $ | 0 | | | | | | $ | 0 | | | | | | $ | 1,486,514 | | | | | | $ | 185,199 | | | | | | $ | 0 | | | | | | $ | 23,077 | | | | | | $ | 1,694,789 | | | |
| |
Disability
|
| | | | $ | 0 | | | | | | $ | 0 | | | | | | $ | 0 | | | | | | $ | 185,199 | | | | | | $ | 0 | | | | | | $ | 23,077 | | | | | | $ | 208,275 | | | |
| |
Involuntary Termination—Not For Cause or Good
Reason Termination |
| | | | $ | 600,000 | | | | | | $ | 3,713 | | | | | | $ | 0 | | | | | | $ | 185,199 | | | | | | $ | 75,000 | | | | | | $ | 23,077 | | | | | | $ | 886,988 | | | |
| |
William D. Barbo
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| |
Voluntary Termination or For Cause Termination
|
| | | | $ | 0 | | | | | | $ | 0 | | | | | | $ | 0 | | | | | | $ | 889,687 | | | | | | $ | 0 | | | | | | $ | 21,156 | | | | | | $ | 910,842 | | | |
| |
Retirement
|
| | | | $ | 0 | | | | | | $ | 0 | | | | | | $ | 2,927,827 | | | | | | $ | 889,687 | | | | | | $ | 0 | | | | | | $ | 21,156 | | | | | | $ | 3,838,670 | | | |
| |
Death
|
| | | | $ | 0 | | | | | | $ | 0 | | | | | | $ | 1,229,822 | | | | | | $ | 889,687 | | | | | | $ | 0 | | | | | | $ | 21,156 | | | | | | $ | 2,140,664 | | | |
| |
Disability
|
| | | | $ | 0 | | | | | | $ | 0 | | | | | | $ | 426,377 | | | | | | $ | 889,687 | | | | | | $ | 0 | | | | | | $ | 21,156 | | | | | | $ | 1,337,219 | | | |
| |
Involuntary Termination—Not for Cause or Good
Reason Termination |
| | | | $ | 1,100,100 | | | | | | $ | 24,482 | | | | | | $ | 0 | | | | | | $ | 889,687 | | | | | | $ | 75,000 | | | | | | $ | 21,156 | | | | | | $ | 2,110,424 | | | |
| |
Birgit Girshick
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| |
Voluntary Termination, Retirement, or For Cause Termination
|
| | | | $ | 0 | | | | | | $ | 0 | | | | | | $ | 0 | | | | | | $ | 1,001,551 | | | | | | $ | 0 | | | | | | $ | 25,000 | | | | | | $ | 1,026,551 | | | |
| |
Death
|
| | | | $ | 0 | | | | | | $ | 0 | | | | | | $ | 1,566,544 | | | | | | $ | 1,113,694 | | | | | | $ | 0 | | | | | | $ | 25,000 | | | | | | $ | 2,705,238 | | | |
| |
Disability
|
| | | | $ | 0 | | | | | | $ | 0 | | | | | | $ | 501,590 | | | | | | $ | 1,113,694 | | | | | | $ | 0 | | | | | | $ | 25,000 | | | | | | $ | 1,640,284 | | | |
| |
Involuntary Termination—Not for Cause or Good
Reason Termination |
| | | | $ | 1,300,000 | | | | | | $ | 7,584 | | | | | | $ | 0 | | | | | | $ | 1,001,551 | | | | | | $ | 75,000 | | | | | | $ | 25,000 | | | | | | $ | 2,409,135 | | | |
| |
Joseph LaPlume
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Voluntary Termination, Retirement, or For Cause Termination | | | | | $ | 0 | | | | | | $ | 0 | | | | | | $ | 0 | | | | | | $ | 447,169 | | | | | | $ | 0 | | | | | | $ | 20,000 | | | | | | $ | 467,169 | | | |
| |
Death
|
| | | | $ | 0 | | | | | | $ | 0 | | | | | | $ | 2,842,842 | | | | | | $ | 555,017 | | | | | | $ | 0 | | | | | | $ | 20,000 | | | | | | $ | 3,417,859 | | | |
| |
Disability
|
| | | | $ | 0 | | | | | | $ | 0 | | | | | | $ | 476,519 | | | | | | $ | 555,017 | | | | | | $ | 0 | | | | | | $ | 20,000 | | | | | | $ | 1,051,536 | | | |
| |
Involuntary Termination—Not for Cause or Good
Reason Termination |
| | | | $ | 1,040,000 | | | | | | $ | 58,038 | | | | | | $ | 0 | | | | | | $ | 447,169 | | | | | | $ | 75,000 | | | | | | $ | 20,000 | | | | | | $ | 1,640,207 | | | |
| |
David R. Smith(4)
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| |
Voluntary Termination, Retirement, or For Cause Termination
|
| | | | $ | 0 | | | | | | $ | 0 | | | | | | $ | 0 | | | | | | $ | 408,820 | | | | | | $ | 0 | | | | | | $ | 0 | | | | | | $ | 408,820 | | | |
| |
Death
|
| | | | $ | 0 | | | | | | $ | 0 | | | | | | $ | 2,269,621 | | | | | | $ | 435,135 | | | | | | $ | 0 | | | | | | $ | 0 | | | | | | $ | 2,704,756 | | | |
| |
Disability
|
| | | | $ | 0 | | | | | | $ | 0 | | | | | | $ | 556,444 | | | | | | $ | 435,135 | | | | | | $ | 0 | | | | | | $ | 0 | | | | | | $ | 991,579 | | | |
| |
Involuntary Termination—Not for Cause or Good
Reason Termination |
| | | | $ | 1,161,362 | | | | | | $ | 2,007 | | | | | | $ | 1,533,518 | | | | | | $ | 408,820 | | | | | | $ | 75,000 | | | | | | $ | 0 | | | | | | $ | 3,180,707 | | | |
| |
Name
|
| | |
Cash
Severance |
| | |
Benefits and
Supplemental Perquisites Continuation |
| | |
Equity
Value(1) |
| | |
Retirement Plan
Benefits |
| | |
Other(2)
|
| | |
Accrued
Vacation |
| | |
Total
|
| | |||||||||||||||||||||
| |
James C. Foster
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Death, Disability, Retirement, Voluntary Termination, and For Cause Termination | | | | | $ | 0 | | | | | | $ | 0 | | | | | | $ | 19,611,475 | | | | | | $ | 30,149,684 | | | | | | $ | 0 | | | | | | $ | 54,319 | | | | | | $ | 49,815,478 | | | |
| | Involuntary Termination Not for Cause or Good Reason Termination | | | | | $ | 8,473,748 | | | | | | $ | 277,731 | | | | | | $ | 19,611,475 | | | | | | $ | 30,149,684 | | | | | | $ | 50,000 | | | | | | $ | 54,319 | | | | | | $ | 58,616,957 | | | |
| |
Flavia H. Pease
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Death, Disability, Retirement, Voluntary Termination, and For Cause Termination | | | | | $ | 0 | | | | | | $ | 0 | | | | | | $ | 2,737,914 | | | | | | $ | 185,199 | | | | | | $ | 0 | | | | | | $ | 23,077 | | | | | | $ | 2,946,189 | | | |
| | Involuntary Termination Not for Cause or Good Reason Termination | | | | | $ | 2,040,000 | | | | | | $ | 20,466 | | | | | | $ | 2,737,914 | | | | | | $ | 185,199 | | | | | | $ | 50,000 | | | | | | $ | 23,077 | | | | | | $ | 5,056,655 | | | |
| |
William D. Barbo
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| |
Death, Disability, Retirement, Voluntary Termination, and For Cause Termination
|
| | | | $ | 0 | | | | | | $ | 0 | | | | | | $ | 3,077,849 | | | | | | $ | 889,687 | | | | | | $ | 0 | | | | | | $ | 21,156 | | | | | | $ | 3,988,691 | | | |
| |
Involuntary Termination Not for Cause or Good Reason Termination
|
| | | | $ | 1,870,170 | | | | | | $ | 68,210 | | | | | | $ | 3,077,849 | | | | | | $ | 889,687 | | | | | | $ | 50,000 | | | | | | $ | 21,156 | | | | | | $ | 5,977,071 | | | |
| |
Birgit Girshick
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| |
Death, Disability, Retirement, Voluntary Termination, and For Cause Termination
|
| | | | $ | 0 | | | | | | $ | 0 | | | | | | $ | 4,238,870 | | | | | | $ | 1,113,694 | | | | | | $ | 0 | | | | | | $ | 25,000 | | | | | | $ | 5,377,564 | | | |
| |
Involuntary Termination Not for Cause or Good Reason Termination
|
| | | | $ | 2,340,000 | | | | | | $ | 24,756 | | | | | | $ | 4,238,870 | | | | | | $ | 1,113,694 | | | | | | $ | 50,000 | | | | | | $ | 25,000 | | | | | | $ | 7,792,320 | | | |
| |
Joseph LaPlume
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Death, Disability, Retirement, Voluntary Termination, and For Cause Termination | | | | | $ | 0 | | | | | | $ | 0 | | | | | | $ | 4,894,274 | | | | | | $ | 555,017 | | | | | | $ | 0 | | | | | | $ | 20,000 | | | | | | $ | 5,469,290 | | | |
| | Involuntary Termination Not for Cause or Good Reason Termination | | | | | $ | 1,768,000 | | | | | | $ | 68,832 | | | | | | $ | 4,894,274 | | | | | | $ | 555,017 | | | | | | $ | 50,000 | | | | | | $ | 20,000 | | | | | | $ | 7,356,122 | | | |
| |
David R. Smith(3)
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Death, Disability, Retirement, Voluntary Termination, and For Cause Termination | | | | | $ | 0 | | | | | | $ | 0 | | | | | | $ | 3,154,526 | | | | | | $ | 435,135 | | | | | | $ | 0 | | | | | | $ | 0 | | | | | | $ | 3,589,661 | | | |
| | Involuntary Termination Not for Cause or Good Reason Termination | | | | | $ | 1,974,315 | | | | | | $ | 4,150 | | | | | | $ | 3,154,526 | | | | | | $ | 435,135 | | | | | | $ | 50,000 | | | | | | $ | 0 | | | | | | $ | 5,618,126 | | | |
| | Year | | | | Summary Compensation Table Total for CEO ($) | | | | Compensation Actually Paid to CEO ($)(1) | | | | Average Summary Compensation Table Total for Other Named Executives ($) (2) | | | | Average Compensation Actually paid to Other Named Executives ($) (1) | | | | Value of Initial Fixed $100 Investment Based on (3) | | | | Net Income ($) | | | | Non- GAAP EPS ($) | | | ||||||||||||||||||||||||||||
| Total Shareholder Return ($) | | | | Peer Group Total Shareholder Return ($) | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| | 2022 | | | | | | | | | | | | ( | | | | | | | | | | | | | ( | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||
| | 2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||||
| | 2020 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Year | | | | Executive(s) | | | | SCT Total | | | | Deduct Current Year Equity Grants(1) | | | | Deduct Change in Value of Pension or Non-qualified Deferred Compensation Earnings from SCT(1) | | | | Add Pension Value Attributable Current Year’s Service | | | | Add Year End Fair Value of Equity Awards Granted in Current Year(2) | | | | Add Change in Value of Prior Years’ Grants that Remained Unvested at Year End(3) | | | | Add Change in Value of Prior Years’ Grants that Vested in Current Year(4) | | | | Compensation Actually Paid | | | ||||||||||||||||||||||||
| | 2022 | | | | CEO | | | | | | | | | | | | | | | | | | — | | | | | | | | | | | | | | | | | | | ( | | | | | | | ( | | | | | | | ( | | | | ||||
| Other Named Executives | | | | | | | | | | | | | | | | | | — | | | | | | | — | | | | | | | | | | | | | ( | | | | | | | ( | | | | | | | ( | | | | ||||||||
| | 2021 | | | | CEO | | | | | | | | | | | | | | | | | | — | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||||
| Other Named Executives | | | | | | | | | | | | | | | | | | — | | | | | | | — | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||||||||
| | 2020 | | | | CEO | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||||
| Other Named Executives | | | | | | | | | | | | | | | | | | — | | | | | | | — | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Most Important Performance Measures | | |
| | | | |
| | | | |
| | | | |
| | |
2022
|
| |
2021
|
| ||||||
Audit fees(1)
|
| | | $ | 6,151,413 | | | | | $ | 6,479,044 | | |
Audit related fees(2)
|
| | | | 2,959,018 | | | | | | 3,258,316 | | |
Tax fees(3)
|
| | | | 980,353 | | | | | | 1,013,393 | | |
All other fees(4)
|
| | | | 646,394 | | | | | | 1,646,751 | | |
Total(5)
|
| | | $ | 10,737,178 | | | | | $ | 12,397,504 | | |
| | |
Twelve Months Ended
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | |
December 31,
2022 |
| |
December 25,
2021 |
| |
December 26,
2020 |
| |
December 28,
2019 |
| |
December 29,
2018 |
| |
December 30,
2017 |
| |
December 31,
2016 |
| |
December 26,
2015 |
| |
December 27,
2014 |
| |
December 28,
2013 |
| |
December 29,
2012 |
| |
December 31,
2011 |
| |
December 25,
2010 |
| |
December 26,
2009 |
| |
December 27,
2008 |
| |||||||||||||||||||||||||||||||||||||||||||||
Net income (loss) attributable to common shareholders
|
| | | $ | 486,226 | | | | | $ | 390,982 | | | | | $ | 364,304 | | | | | $ | 252,019 | | | | | $ | 226,373 | | | | | $ | 123,355 | | | | | $ | 154,765 | | | | | $ | 149,313 | | | | | $ | 126,698 | | | | | $ | 102,828 | | | | | $ | 97,295 | | | | | $ | 109,566 | | | | | $ | (336,669) | | | | | $ | 114,441 | | | | | $ | (524,505) | | |
Less: Income (loss) from
discontinued operations, net of income taxes |
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 1,506 | | | | | | (137) | | | | | | 280 | | | | | | (950) | | | | | | (1,726) | | | | | | (1,265) | | | | | | (4,252) | | | | | | (5,545) | | | | | | (8,012) | | | | | | 1,399 | | | | | | 3,283 | | |
Net income (loss) from continuing
operations attributable to common shareholders |
| | | | 486,226 | | | | | | 390,982 | | | | | | 364,304 | | | | | | 252,019 | | | | | | 224,867 | | | | | | 123,492 | | | | | | 154,485 | | | | | | 150,263 | | | | | | 128,424 | | | | | | 104,093 | | | | | | 101,547 | | | | | | 115,111 | | | | | | (328,657) | | | | | | 113,042 | | | | | | (527,788) | | |
Add back: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Amortization related to acquisitions
|
| | | | 146,934 | | | | | | 128,148 | | | | | | 118,618 | | | | | | 90,867 | | | | | | 64,831 | | | | | | 41,370 | | | | | | 42,746 | | | | | | 29,374 | | | | | | 25,957 | | | | | | 17,806 | | | | | | 18,067 | | | | | | 21,795 | | | | | | 24,405 | | | | | | 25,717 | | | | | | 26,725 | | |
Severance and executive transition costs
|
| | | | 4,088 | | | | | | 4,718 | | | | | | 7,586 | | | | | | 11,458 | | | | | | 8,680 | | | | | | 3,278 | | | | | | 8,472 | | | | | | 6,173 | | | | | | 7,792 | | | | | | 3,218 | | | | | | 2,580 | | | | | | 5,462 | | | | | | 16,504 | | | | | | 16,344 | | | | | | — | | |
Site consolidation costs, impairments, and other
items(2) |
| | | | 13,405 | | | | | | 3,468 | | | | | | 6,457 | | | | | | 4,283 | | | | | | 864 | | | | | | 18,645 | | | | | | 11,849 | | | | | | 2,240 | | | | | | 7,136 | | | | | | 21,381 | | | | | | 3,963 | | | | | | 473 | | | | | | 384,896 | | | | | | 3,939 | | | | | | 706,689 | | |
Adjustment of acquisition-related
contingent consideration and related items |
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (721) | | | | | | 2,865 | | | | | | — | | | | | | — | | |
Operating losses(3)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 5,517 | | | | | | 2,600 | | | | | | 3,371 | | | | | | 3,738 | | | | | | 6,471 | | | | | | 13,387 | | | | | | 3,988 | | | | | | — | | |
Acquisition-related
adjustments(4) |
| | | | 18,566 | | | | | | 15,867 | | | | | | 19,623 | | | | | | 39,439 | | | | | | 19,184 | | | | | | 6,687 | | | | | | 22,702 | | | | | | 14,513 | | | | | | 6,688 | | | | | | 1,752 | | | | | | 3,774 | | | | | | 215 | | | | | | 8,319 | | | | | | 3,246 | | | | | | 1,125 | | |
Government billing adjustment and related expenses
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 150 | | | | | | 634 | | | | | | 477 | | | | | | 848 | | | | | | 2,402 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Acquisition agreement termination fee
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 30,000 | | | | | | — | | | | | | — | | |
Gain on settlement of life insurance policy
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (7,710) | | | | | | — | | | | | | — | | | | | | — | | |
U.S. pension curtailment
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (3,276) | | |
Gain on sale of U.K. real
estate |
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (839) | | | | | | — | | |
Reversal of an indemnification
asset associated with acquisition and corresponding interest(5) |
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 54 | | | | | | 10,411 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Write-off of deferred financing costs and fees related to debt refinancing
|
| | | | — | | | | | | 26,089 | | | | | | — | | | | | | 1,605 | | | | | | 5,060 | | | | | | — | | | | | | 987 | | | | | | 721 | | | | | | — | | | | | | 645 | | | | | | — | | | | | | 1,450 | | | | | | 4,542 | | | | | | — | | | | | | — | | |
Loss on sale of auction rate securities
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 712 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
(Gain) loss on bargain
purchase(6) |
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (277) | | | | | | 15 | | | | | | (9,837) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Convertible debt
accounting(7) |
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 6,710 | | | | | | 14,741 | | | | | | 13,978 | | | | | | 12,948 | | | | | | 11,106 | | | | | | 8,432 | | |
Gain on divestiture of CDMO business
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (10,577) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Debt forgiveness associated with a
prior acquisition(8) |
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (1,863) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Deferred tax revaluation
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 763 | | |
Tax benefit from disposition of Phase I clinical business
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (11,111) | | | | | | — | | | | | | — | | | | | | — | | |
Massachusetts tax law change
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 1,897 | | |
Reduction of tax benefits – Charles River
Massachusetts |
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 719 | | | | | | — | | |
Costs and taxes associated with corporate legal entity restructuring and
repatriation |
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 1,637 | | | | | | 15,689 | | | | | | (1,084) | | | | | | (4,045) | | |
Venture capital and strategic equity investment losses
(gains) |
| | | | 26,775 | | | | | | 30,419 | | | | | | (100,861) | | | | | | (20,707) | | | | | | (15,928) | | | | | | (22,657) | | | | | | (10,285) | | | | | | (3,824) | | | | | | (9,343) | | | | | | (5,864) | | | | | | 618 | | | | | | (869) | | | | | | 579 | | | | | | — | | | | | | — | | |
Loss due to U.S. Pension termination
|
| | | | — | | | | | | — | | | | | | 10,283 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | |
Twelve Months Ended
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | |
December 31,
2022 |
| |
December 25,
2021 |
| |
December 26,
2020 |
| |
December 28,
2019 |
| |
December 29,
2018 |
| |
December 30,
2017 |
| |
December 31,
2016 |
| |
December 26,
2015 |
| |
December 27,
2014 |
| |
December 28,
2013 |
| |
December 29,
2012 |
| |
December 31,
2011 |
| |
December 25,
2010 |
| |
December 26,
2009 |
| |
December 27,
2008 |
| |||||||||||||||||||||||||||||||||||||||||||||
Gain due to sale of RMS Japan operations
|
| | | | — | | | | | | (22,656) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Gain due to sale of Avian
business |
| | | | (123,524) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Other(9)
|
| | | | 5,285 | | | | | | (2,942) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Tax effect of non-GAAP adjustments:
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Tax effect from U.S. Tax Reform(10)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (5,450) | | | | | | 78,537 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Tax effect from divestiture of CDMO business
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (1,000) | | | | | | 17,705 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Non-cash tax provision (benefit)
related to international financing structure(11) |
| | | | 4,648 | | | | | | 4,809 | | | | | | 4,444 | | | | | | (19,787) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Reversal of uncertain tax position
associated with acquisition and corresponding interest(5) |
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (10,411) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Enacted tax law changes
|
| | | | (382) | | | | | | 10,036 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Tax effect of the remaining non-GAAP adjustments and certain other tax items
|
| | | | (11,399) | | | | | | (58,404) | | | | | | (18,953) | | | | | | (24,811) | | | | | | (17,166) | | | | | | (12,286) | | | | | | (18,744) | | | | | | (18,672) | | | | | | (11,483) | | | | | | (16,976) | | | | | | (16,832) | | | | | | (15,388) | | | | | | (59,489) | | | | | | (22,228) | | | | | | (15,970) | | |
Net income from continuing
operations attributable to common shareholders, excluding specified charges (Non- GAAP) |
| | | $ | 570,622 | | | | | $ | 530,534 | | | | | $ | 411,501 | | | | | $ | 334,366 | | | | | $ | 283,942 | | | | | $ | 242,204 | | | | | $ | 212,915 | | | | | $ | 176,945 | | | | | $ | 158,619 | | | | | $ | 138,538 | | | | | $ | 132,908 | | | | | $ | 130,793 | | | | | $ | 125,988 | | | | | $ | 153,950 | | | | | $ | 194,552 | | |
Weighted average shares outstanding – Basic
|
| | | | 50,812 | | | | | | 50,293 | | | | | | 49,550 | | | | | | 48,730 | | | | | | 47,947 | | | | | | 47,481 | | | | | | 47,014 | | | | | | 46,496 | | | | | | 46,627 | | | | | | 47,740 | | | | | | 47,912 | | | | | | 50,823 | | | | | | 62,561 | | | | | | 65,366 | | | | | | 67,274 | | |
Effect of dilutive securities: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
2.25% senior convertible debentures
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 776 | | |
Stock options, restricted stock
units, performance stock units, and contingently issued restricted stock |
| | | | 489 | | | | | | 1,132 | | | | | | 1,061 | | | | | | 963 | | | | | | 1,071 | | | | | | 1,083 | | | | | | 944 | | | | | | 1,138 | | | | | | 931 | | | | | | 749 | | | | | | 494 | | | | | | 495 | | | | | | 558 | | | | | | 268 | | | | | | 1,010 | | |
Warrants
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 2 | | | | | | 87 | | |
Weighted average shares outstanding − Diluted
|
| | | | 51,301 | | | | | | 51,425 | | | | | | 50,611 | | | | | | 49,693 | | | | | | 49,018 | | | | | | 48,564 | | | | | | 47,958 | | | | | | 47,634 | | | | | | 47,558 | | | | | | 48,489 | | | | | | 48,406 | | | | | | 51,318 | | | | | | 63,120 | | | | | | 65,636 | | | | | | 69,147 | | |
Earnings per share from continuing
operations attributable to common shareholders |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Basic
|
| | | $ | 9.57 | | | | | $ | 7.77 | | | | | $ | 7.35 | | | | | $ | 5.17 | | | | | $ | 4.69 | | | | | $ | 2.60 | | | | | $ | 3.28 | | | | | $ | 3.23 | | | | | $ | 2.76 | | | | | $ | 2.18 | | | | | $ | 2.12 | | | | | $ | 2.26 | | | | | $ | (5.25) | | | | | $ | 1.73 | | | | | $ | (7.85) | | |
Diluted
|
| | | $ | 9.48 | | | | | $ | 7.60 | | | | | $ | 7.20 | | | | | $ | 5.07 | | | | | $ | 4.59 | | | | | $ | 2.54 | | | | | $ | 3.22 | | | | | $ | 3.15 | | | | | $ | 2.70 | | | | | $ | 2.15 | | | | | $ | 2.10 | | | | | $ | 2.24 | | | | | $ | (5.25) | | | | | $ | 1.72 | | | | | $ | (7.85) | | |
Basic, excluding non-GAAP adjustments
|
| | | $ | 11.23 | | | | | $ | 10.55 | | | | | $ | 8.30 | | | | | $ | 6.86 | | | | | $ | 5.92 | | | | | $ | 5.10 | | | | | $ | 4.53 | | | | | $ | 3.81 | | | | | $ | 3.40 | | | | | $ | 2.90 | | | | | $ | 2.77 | | | | | $ | 2.57 | | | | | $ | 2.01 | | | | | $ | 2.36 | | | | | $ | 2.89 | | |
Diluted, excluding non-GAAP
adjustments |
| | | $ | 11.12 | | | | | $ | 10.32 | | | | | $ | 8.13 | | | | | $ | 6.73 | | | | | $ | 5.80 | | | | | $ | 4.99 | | | | | $ | 4.44 | | | | | $ | 3.71 | | | | | $ | 3.34 | | | | | $ | 2.86 | | | | | $ | 2.75 | | | | | $ | 2.55 | | | | | $ | 2.00 | | | | | $ | 2.35 | | | | | $ | 2.81 | | |